Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease

Release of mitochondrial cytochrome c resulting in downstream activation of cell death pathways has been suggested to play a role in neurologic diseases featuring cell death. However, the specific biologic importance of cytochrome c release has not been demonstrated in Huntington's disease (HD). To evaluate the role of cytochrome c release, we screened a drug library to identify new inhibitors of cytochrome c release from mitochondria. Drugs effective at the level of purified mitochondria were evaluated in a cellular model of HD. As proof of principle, one drug was chosen for in depth evaluation in vitro and a transgenic mouse model of HD. Our findings demonstrate the utility of mitochondrial screening to identify inhibitors of cell death and provide further support for the important functional role of cytochrome c release in HD. Given that many of these compounds have been approved by the Food and Drug Administration for clinical usage and cross the blood–brain barrier, these drugs may lead to trials in patients.

[1]  B. Kristal,et al.  Kinetic Model for Ca2+-induced Permeability Transition in Energized Liver Mitochondria Discriminates between Inhibitor Mechanisms* , 2008, Journal of Biological Chemistry.

[2]  John Calvin Reed,et al.  Protective role of Cop in Rip2/caspase-1/caspase-4-mediated HeLa cell death. , 2006, Biochimica et biophysica acta.

[3]  R. Swanson,et al.  Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Ninds Net-Pd Investigators.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[5]  R. Elble,et al.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease , 2006, Neurology.

[6]  R. Ferrante,et al.  Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. , 2006, Biochimica et biophysica acta.

[7]  John Calvin Reed,et al.  Dysregulation of Receptor Interacting Protein-2 and Caspase Recruitment Domain Only Protein Mediates Aberrant Caspase-1 Activation in Huntington's Disease , 2005, The Journal of Neuroscience.

[8]  C. Ross,et al.  Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model , 2005, Neurobiology of Disease.

[9]  B. Kristal,et al.  Comparative kinetic analysis reveals that inducer-specific ion release precedes the mitochondrial permeability transition. , 2005, Biochimica et biophysica acta.

[10]  M. Zoratti,et al.  Mitochondrial permeability transitions: how many doors to the house? , 2005, Biochimica et biophysica acta.

[11]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[12]  P. Chan.  Mitochondria and Neuronal Death/Survival Signaling Pathways in Cerebral Ischemia , 2004, Neurochemical Research.

[13]  A. Tobin,et al.  A cell-based screen for drugs to treat Huntington's disease , 2004, Neurobiology of Disease.

[14]  M. Beal,et al.  Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology , 2004, The Journal of experimental medicine.

[15]  F. Bregegere,et al.  Replicative senescence enhances apoptosis induced by pemphigus autoimmune antibodies in human keratinocytes , 2004, FEBS letters.

[16]  M. Feinmesser,et al.  Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins , 2004, Apoptosis.

[17]  John Calvin Reed,et al.  Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Tison,et al.  Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease , 2003, Annals of neurology.

[19]  S. Hersch,et al.  Minocycline is protective in a mouse model of Huntington's disease , 2003, Annals of neurology.

[20]  R. Ferrante,et al.  Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Bates,et al.  Minocycline and doxycycline are not beneficial in a model of Huntington's disease , 2003, Annals of neurology.

[22]  Robert M Friedlander,et al.  Apoptosis and caspases in neurodegenerative diseases. , 2003, The New England journal of medicine.

[23]  R. Jensen,et al.  Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. , 2002, Physiological genomics.

[24]  T. Dawson,et al.  Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.

[25]  V. Yong,et al.  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. , 2002, Brain : a journal of neurology.

[26]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[27]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[28]  R. Curi,et al.  Antiapoptotic effect of dipyrone on HL-60, Jurkat and Raji cell lines submitted to UV irradiation, arachidonic acid and cycloheximide treatments. , 2001, International immunopharmacology.

[29]  S. Gassó,et al.  Antioxidant compounds and Ca2+ pathway blockers differentially protect against methylmercury and mercuric chloride neurotoxicity , 2001, Journal of neuroscience research.

[30]  Xu Luo,et al.  Endonuclease G is an apoptotic DNase when released from mitochondria , 2001, Nature.

[31]  V. Ona,et al.  Minocycline Reduces Traumatic Brain Injury-mediated Caspase-1 Activation, Tissue Damage, and Neurological Dysfunction , 2001, Neurosurgery.

[32]  D. Rigamonti,et al.  Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing* , 2001, The Journal of Biological Chemistry.

[33]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[34]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[35]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[36]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[37]  A. Hackam,et al.  Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.

[38]  P. Chan,et al.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Luca Scorrano,et al.  Mitochondria and cell death. Mechanistic aspects and methodological issues. , 1999, European journal of biochemistry.

[40]  M. Beal,et al.  Mitochondria, NO and neurodegeneration. , 1999, Biochemical Society symposium.

[41]  M. Crompton,et al.  The mitochondrial permeability transition pore. , 1999, Biochemical Society symposium.

[42]  J. Penney,et al.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.

[43]  L. Scorrano,et al.  Mitochondria and cell death. Mechanistic aspects and methodological issues. , 1999, European journal of biochemistry.

[44]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[46]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[47]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[48]  T. Wieloch,et al.  Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. , 1996, Stroke.

[49]  R. Busto,et al.  Ischemia‐Induced Extracellular Release of Serotonin Plays a Role in CA1 Neuronal Cell Death in Rats , 1992, Stroke.

[50]  B. Silvestrini,et al.  The effect of gossypol and Lonidamine on electron transport in Ehrlich ascites tumor mitochondria. , 1984, Experimental and molecular pathology.